Vertex Pharmaceuticals Inc. of Cambridge, Mass., has appointedRobert Schooley to its scientific advisory board. Schooley is thedirector of the infectious diseases division of the University ofColorado Health Sciences Center, as well as a professor ofmedicine at the University and staff physician for the DenverVeterans Affairs Medical Center.

Parexel International Corp. of Waltham, Mass., announced thatHolger Franke has joined the company's European operations asgeneral manager of the central region, based in Berlin. Frankewas president of the Clinical Research Foundation, a German-based independent pharmaceutical research organizationformerly owed by Boehringer Ingelheim.

William Sharp, a vice president of Phytopharmaceuticals Inc., asubsidiary of Escagenetics Corp. of San Carlos, Calif., has beenappointed dean of research at Rutgers University's Cook Collegeand director of research of the university's New Jerseyagricultural experiment station. Sharp will retain a position onPhytopharmaceuticals' scientific advisory board.

Gensia Europe Ltd., a wholly owned subsidiary of Gensia Inc. ofSan Diego, has appointed Stewart Siddall to its board ofdirectors. Siddall is president of the Association of the BritishPharmaceutical Industry.

Seragen Inc. of Hopkinton, Mass., has hired Anthony Clementoas vice president for regulatory affairs and quality. Clementojoined Seragen from Centocor Inc., where he was seniordirector of worldwide regulatory affairs.

Michael Silverman has joined Telor OphthalmicPharmaceuticals Inc. as executive director of clinical research.Silverman joins the Woburn, Mass., company from SandozResearch Institute, where he was director of clinical researchand deputy head.

Michael Riordan, founder and president of Gilead Sciences Inc.,will take on the additional post of chairman of the board ofdirectors of the Foster City, Calif., company.

Ivax Corp. of Miami has promoted John Whisnant to senior vicepresident of research and development of Baker NortonPharmaceuticals Inc., one of Ivax's subsidiaries.

Oncogene Science Inc. of Uniondale, N.Y., promoted WalterCarney to the new position of divisional vice president,diagnostics and research products.

Robert Kunze has joined the board of directors ofImmunoPharmaceutics Inc. of San Diego. He has been generalpartner of Hambrecht & Quist Life Science Venture Partnerssince its formation in 1987.

Cambridge NeuroScience Inc. of Cambridge, Mass., hired HeikkiHakkarainen as vice president of clinical development.Hakkarainen had been Ciba-Geigy Corp.'s international projectleader for neuroprotective agents.

The Phytopharmaceuticals Inc. subsidiary of Escagenetics Corp.has named Meinhart Zenk, John Cassady and William Sharp toits scientific advisory board. Zenk, professor and chairman ofthe Institute of Pharmaceutical Biology at the University ofMunich, will chair the advisory board of the San Carlos, Calif.,company.

William Cagney has joined Seragen Inc. as its director ofoperations. Cagney came to the Hopkinton, Mass., companyfrom Repligen Corp., where he was the director of cell culturemanufacturing.

Alexander Barkas is the new chairman of the board of PaloAlto, Calif.-based Geron Corp. Barkas, a partner with KleinerPerkins Caufield & Byers, a major Geron investor, served as thecompany's founding president and chief executive officer. He isalso a director at Khepri Pharmaceuticals, RiboGene and BioStar.

Canji Inc. of San Diego has hired Bryan Finkel as vice presidentfor development and regulatory affairs, Richard Gregory asdirector of molecular biology, and Beth Meyers Hutchins asdirector of analytical technology. Finkel was Genentech Inc.'sdirector of the department of pharmaceutical sciences, Gregoryhad been Genzyme Inc.'s principal scientist for molecularbiology and gene therapy, and Hutchins came from Genentech'sdepartment of medicinal and analytical chemistry.

(c) 1997 American Health Consultants. All rights reserved.